Experimental cell therapy takes on Hard-to-Treat myeloma

NCT ID NCT04674813

Completed Disease control Sponsor: Juno Therapeutics, a Subsidiary of Celgene Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new cell therapy called CC-95266 in 130 people with multiple myeloma that had come back or stopped responding to treatment. Participants also received chemotherapy drugs to prepare their bodies for the cell infusion. The main goals were to check safety and find the right dose, while also looking at how well the treatment worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-95266 (a cell therapy) given with chemotherapy drugs fludarabine, cyclophosphamide, and bendamustine
What this could lead to: If successful, this could point toward a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong: This is an early phase 1 trial focused on safety, so it is too soon to know if the treatment works. Side effects from the cell therapy and chemotherapy may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Local Institution - 001

Nashville, Tennessee, 37203, United States
Local Institution - 002

Denver, Colorado, 80218, United States
Local Institution - 003

Seattle, Washington, 98104, United States
Local Institution - 005

Birmingham, Alabama, 10016, United States
Local Institution - 006

Dallas, Texas, 75390, United States
Local Institution - 008

Baltimore, Maryland, 21201, United States
Local Institution - 009

Duarte, California, 91010-301, United States
Local Institution - 010

Boston, Massachusetts, 02215, United States
Local Institution - 011

New York, New York, 10029, United States
Local Institution - 012

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.